Nature Reviews Drug Discovery contents December 2012 Volume 11 Number 12 pp 887-973

Advertisement
Proseek® Protein Biomarker Discovery Service Look deeper into the proteome. Promising Discoveries; analyze biomarkers in multiplex reactions using just a few microliters of sample. Delivering quality data; analyze up to 96 biomarkers in parallel with excellent analytical performance. www.olink.com
TABLE OF CONTENTS
December 2012 Volume 11 Number 12
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month Featured article: A guide to drug discovery  Featured article: Protein kinase C, an elusive therapeutic target? Daria Mochly-Rosen, Kanad Das & Kevin V. Grimes
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management. Click here for more information on Alzheimer's partnering opportunities.
In this issue p887 | doi:10.1038/nrd3910 Full Text
Comment: Phase I trials of targeted anticancer drugs: a need to refocus Ernest C. Borden & Afshin Dowlati p889 | doi:10.1038/nrd3909
NEWS AND ANALYSIS		Top
GlaxoSmithKline opens the door on clinical data sharing Charlotte Harrison p891 | doi:10.1038/nrd3907 Moves to release more data from clinical trials could provide unprecedented opportunities to understand disease biology and drug effects. PDF
Cyclin-dependent kinase inhibitors move into Phase III Malini Guha p892 | doi:10.1038/nrd3908 After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase inhibitors are beginning. PDF
NEWS IN BRIEF FDA approval of oral arthritis drug marks a first for Pfizer | Phase III failure of cardiovascular blockbuster hope dissected p895 | doi:10.1038/nrd3911 PDF
BIOBUSINESS BRIEFS Deal watch: Merck invests in pioneering cytomegalovirus programme Sarah Crunkhorn p896 | doi:10.1038/nrd3905 PDF
BIOBUSINESS BRIEFS Trial watch: Phase III success for first-in-class pulmonary hypertension drug Man Tsuey Tse p896 | doi:10.1038/nrd3906 PDF
PATENT WATCH Patent policies round-up | India rejects pegylated interferon patent | Roche's remaining Boniva patent held invalid | Modulating PKC Charlotte Harrison p898 | doi:10.1038/nrd3912 PDF
AN AUDIENCE WITH Chris Lipinski p900 | doi:10.1038/nrd3895 Chris Lipinski, originator of the 'rule of five' guidelines for predicting the oral bioavailability of drug candidates, discusses their impact as well as efforts to expand drug-like chemical space and drug repositioning initiatives. PDF
FROM THE ANALYST'S COUCH Factors influencing non-approval of new drugs in Europe Michelle Putzeist, Aukje K. Mantel-Teeuwisse, Bo Aronsson, Malcolm Rowland, Christine C. Gispen-de Wied, Spiros Vamvakas, Arno W. Hoes, Hubert G. M. Leufkens & Hans-Georg Eichler p903 | doi:10.1038/nrd3894 An analysis of recent approved and failed marketing applications for new drugs evaluated by the European Medicines Agency highlights the factors that are most likely to be associated with non-approval. PDF
RESEARCH HIGHLIGHTS Top Drug screening: A MuSIC-al way to identify drug pairs p905 | doi:10.1038/nrd3898 PDF Analgesics: Deadly snake venom for pain relief? p906 | doi:10.1038/nrd3897 PDF Neurodegenerative diseases: Novel route to neuroprotection p906 | doi:10.1038/nrd3899 PDF Metabolic disorders: Browning fat p907 | doi:10.1038/nrd3896 PDF G protein-coupled receptors: Spinning a native GPCR structure p908 | doi:10.1038/nrd3900 PDF IN BRIEF Obesity and diabetes: Targeting lipid transport in diabetes | Anticancer drugs: Imatinib hits anaplastic large cell lymphoma | Cardiovascular disease: Inhibiting microRNA-34 benefits heart disease | Immune regulation: Disassembling antibody-receptor complexes PDF Drug Discovery JOBS of the week Postdoctoral studies; in vivo drug discovery using zebrafish Karolinska Institute, Cell and Molecular Biology Faculty Positions DGIST (Daegu Geyongbuk Institute of Science & Technology) Director Research and Drug Development Children's Tumor Foundation PhD Position: Functionalized Inorganic Materials for Water Remediation and Drug Delivery University of Southern Denmark, Department of Physics, Chemistry and Pharmacy More Science jobs from Drug Discovery EVENT Active Pharmaceutical Ingredient (API) and Drug Product Specifications 12.-14.12.12 Berlin, Germany More science events from
Advertisement
Human genome and exome interpretation solutions for drug discovery Knome provides end-to-end human genome and exome interpretation solutions for pharmaceutical researchers seeking to identify genetic variation contributing to drug response. Services include whole genome and exome sequencing, comprehensive annotation, project-driven curation, in-depth interpretation, and variant shortlisting. Learn more.
PERSPECTIVES		Top
OPINION Article series: A guide to drug discovery Reducing safety-related drug attrition: the use of in vitro pharmacological profiling Joanne Bowes, Andrew J. Brown, Jacques Hamon, Wolfgang Jarolimek, Arun Sridhar, Gareth Waldron & Steven Whitebread p909 | doi:10.1038/nrd3845 In vitro pharmacological profiling is playing an increasing part in identifying undesirable off-target effects of candidate drugs earlier in the drug discovery process. In this article, authors from four large pharmaceutical companies share their views on the rationale, strategies and methodologies for in vitro pharmacological profiling, and recommend a minimal panel of targets for screening. Abstract | Full Text | PDF
REVIEWS		Top
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family Jenna L. Riffell, Christopher J. Lord & Alan Ashworth p923 | doi:10.1038/nrd3868 Tankyrases — members of the poly(ADP-ribose) polymerase (PARP) protein superfamily — are involved in diverse cellular processes, including WNT signalling and telomere maintenance. Here, the authors describe the biology of tankyrases and the discovery of tankyrase-specific inhibitors, which could have broad clinical utility. The challenges that lie ahead for the clinical development of PARP family inhibitors in general are also examined. Abstract | Full Text | PDF
Protein kinase C, an elusive therapeutic target? Daria Mochly-Rosen, Kanad Das & Kevin V. Grimes p937 | doi:10.1038/nrd3871 The protein kinase C (PKC) family of highly related protein kinases are implicated in several diseases and have been a major focus of drug discovery efforts. However, no single drug specifically targeting a PKC isozyme has yet received approval. Here, Mochly-Rosen and colleagues review the efforts, challenges and opportunities in developing PKC modulators. Abstract | Full Text | PDF
The potential of biologics for the treatment of asthma Girolamo Pelaia, Alessandro Vatrella & Rosario Maselli p958 | doi:10.1038/nrd3792 Here, the authors discuss how cytokines could be used as therapeutic targets for individuals with asthma that is inadequately controlled using current therapies. They also highlight the need for phenotyping asthma subtypes in order to achieve the best possible patient-focused treatment. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: The predicated demise of racemic new molecular entities is an exaggeration Israel Agranat, Silvya R. Wainschtein & Enav Z. Zusman p972 | doi:10.1038/nrd3657-c1 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.